Background More than 429,000 patients worldwide are diagnosed with bladder cancer each year and muscle-invasive bladder cancer has an especially poor outcome. The median age at diagnosis is over 70 ...

Bavencio maintenance therapy is effective and generally well-tolerated in urothelial cancer patients, with minimal side effects for most. Patients on Bavencio lived an average of 17 months, with ...

Using the Shiny method, a more nuanced approach to meta-analysis, investigators determined that enfortumab vedotin plus pembrolizumab outperforms chemotherapy-based regimens for urothelial carcinoma.

Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes. Among patients with advanced urothelial carcinoma who ...

Urothelial carcinoma, a common urinary system malignancy with marked heterogeneity, leads to significantly varied clinical outcomes among patients, creating major treatment challenges. HER2, a key ...

Credit: Thinkstock Investigators explored the potential of a noninvasive ctDNA assay as a predictive biomarker for advanced or metastatic urothelial cancer. Increases in circulating tumor DNA fraction ...

For patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) (EV+P) continued to ...

By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.

A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...